National and Kapodistrian University of Athens
Έλεγχος της έκφρασης του υποδοχέα PD-L1 σε θηλώδη καρκινώματα θυρεοειδούς αδένα, διερεύνηση της μεταξύ τους σχέσης και της χρήσης του ως διαγνωστικό και προγνωστικό δείκτη
Abstract
dc:descriptionBackground: Programmed cell death ligand 1 (PD-L1) expression is a well-established prerequisite for the use of immune checkpoint inhibitors and is increasingly recognized as a prognostic biomarker in various malignancies. However, its prognostic significance in thyroid cancer (TC), particularly papillary thyroid carcinoma (PTC), remains largely unexplored and somewhat controversial, with findings to date being limited and inconsistent. The aim of this study was to evaluate PD-L1 expression in a well-characterized cohort of patients with PTC and assess its association with key clinicopathological features and clinical outcomes. Materials and Methods: This retrospective, single-center cohort study included patients with histologically confirmed PTC who underwent thyroid surgery at the “Korgialeneio – Benakeio” General Hospital of Athens in Greece between 2007 and 2018. Formalin-fixed, paraffin-embedded (FFPE) tumor samples were assessed for PD-L1 expression using immunohistochemistry and scored using the combined positive score (CPS), with CPS ≥10 indicating PD-L1 positivity. Clinicopathological data were collected through review of patients’ medical records and postoperative histopathology reports, and associations with PD-L1 status were analyzed. Disease-free recurrence (DFS) and overall survival (OS) were also evaluated using Kaplan–Meier methods. Results: Among 81 PTC patients included in this study (median age: 48 years, 83% female), PD-L1 positivity (CPS ≥10) was observed in 45.7%. CPS ≥10 status was significantly associated with larger tumor size, higher pT stage (pT3–pT4), extrathyroidal extension, lymph node metastasis, and the presence of aggressive histologic variants. Coexisting Hashimoto’s thyroiditis and higher rates of radioactive iodine therapy (RAI) were also more common in the PD-L1–positive group. At a median follow-up of 9 years, the overall recurrence rate was 8.6%, with significantly higher recurrence and shorter DFS among patients with CPS ≥10 tumors. OS remained high across both groups. Conclusions: PD-L1 expression was present in nearly half of this real-world Greek PTC cohort and was associated with multiple adverse clinicopathological features and an increased risk of recurrence. These findings support the potential utility of PD-L1 as a prognostic biomarker in PTC and may inform postoperative risk stratification and follow-up strategies.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Spyroulia, Dimitra
- Σπυρούλια, Δήμητρα
Subjects
dc:subject × 22- Θηλώδες καρκίνωμα θυρεοειδούς
- Καρκίνος θυρεοειδούς
- Υποδοχέας προγραμματισμένου κυτταρικού θανάτου PD-L1
- Κλινικοπαθολογοανατομικός δείκτης
- Προγνωστικός βιοδείκτης
- Σημεία ελέγχου του ανοσοποιητικού
- Ανοσολογικό μικροπεριβάλλον του όγκου
- Ανοσοϊστοχημεία
- Papillary thyroid carcinoma
- Thyroid cancer
- Programmed death-ligand 1 (PD-L1);
- Clinicopathological marker
- Prognostic biomarker
- Immune checkpoint
- Tumor immune microenvironment
- Immunohistochemistry
- Επιστήμες Υγείας
- Ιατρική και Επιστήμες Υγείας
- Επαγγέλματα υγείας
- Health Sciences
- Medical and Health Sciences
- Health Professions
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/60177